{Reference Type}: Case Reports
{Title}: Reversible Alopecia Secondary to OROS Methylphenidate.
{Author}: Núñez-Garces M;Sánchez-Gayango A;Romero-Pérez C;
{Journal}: Rev Colomb Psiquiatr (Engl Ed)
{Volume}: 49
{Issue}: 3
{Year}: Jul 2020 0
暂无{DOI}: 10.1016/j.rcp.2018.09.003
{Abstract}: <B>BACKGROUND: </B>Attention deficit hyperactivity disorder has a prevalence of 1-4% of the Spanish school population. Its treatment consists of giving amphetamine derivatives and, recently, non-stimulant drugs, without finding any differences in efficacy in the studies performed.<BR><B>METHODS: </B>A 7-year-old girl was referred from neurology due to learning delay and behaviour disorders. Diagnosed as likely ADHD, treatment was started with immediate release methylphenidate, and later with an osmotic release oral system (OROS) methylphenidate. When alopecia areata appeared, this treatment was withdrawn. After the re-introduction of modified release methylphenidate 30:70, symptom control was achieved without the appearance of alopecia.<BR><B>CONCLUSIONS: </B>There is a published history of two cases of alopecia areata with OROS methylphenidate that resolved after increasing the dose of the drug without clearly knowing the reason for this event. There is no consensus on the priority use of the immediate release formula or the OROS methylphenidate.